Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies.
Major depressive disorder (MDD) is a heterogeneous condition with a variable response to a wide range of treatments. Despite intensive efforts, no biomarker has been identified to date that can reliably predict response or non-response to any form of treatment, nor has one been identified that can be used to identify those at high risk of developing treatment-resistant depression (ie, non-response to a sequence of treatments delivered for adequate duration and intensity). This manuscript reviews some past areas of research that have proved informative, such as studies using indexes of hypercortisolism or sleep disturbance, and more recent research findings using measures of inflammation and different indicators of regional cortical activation to predict treatment response. It is concluded that, although no method has yet been demonstrated to be sufficiently accurate to be applied in clinical practice, progress has been made. It thus seems likely that--at some point in the not-too-distant future--it will be possible to prospectively identify, at least for some MDD patients, the likelihood of response or non-response to cognitive therapy or various antidepressant medications.
Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Michael E
ME
Thase
D000928:Antidepressive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis*; D015928:Cognitive Behavioral Therapy; D003865:Major Depressive Disorder / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D016896:Treatment Outcome
D000928:Antidepressive Agents; D015415:Biomarkers
antidepressant; biomarker; cognitive behavior therapy; prediction; treatment response